Premium
ECT‐induced prolactin release: Effect of sex, electrode placement and serotonin uptake inhibition
Author(s) -
Zis A. P.,
Goumeniouk A. D.,
Clark C. M.,
Grant B. E. K.,
Remick R. A.,
Lam R. W.,
Garland E. J.
Publication year - 1991
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470060210
Subject(s) - methysergide , ketanserin , ritanserin , clomipramine , serotonin , medicine , endocrinology , antagonist , prolactin , pharmacology , 5 ht receptor , placebo , fluoxetine , receptor antagonist , chemistry , psychology , receptor , hormone , alternative medicine , pathology
We and others have previously reported that the non‐specific serotonin receptor antagonist methysergide inhibits the PRL response to ECT wheras the 5HT‐2 antagonists ketanserin and ritanserin have no effect. In the present study the effect of serotonin uptake inhibition on this neuroendocrine response was examined in two separate placebo‐controlled experiments. According to our results neither clomipramine (25 mg orally) nor fluoxetine (20 mg orally) affected the PRL response to ECT. An analysis of the placebo day data from 32 subjects indicates that a high PRL response to ECT is associated with female sex and bilateral electrode placement.